Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam J Adler

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Current Cancer Drug Targets|February 20, 2007
Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormonesAdam J Adler
Immunological Investigations|February 21, 2024
Letter from the Editor and Introduction to the 2023 Thematic IssueAdam J Adler
Current Immunology Reviews|April 23, 2010
Peripheral Tolerization of Effector and Memory T Cells: Implications for Autoimmunity and Tumor-ImmunityAdam J Adler
Immunological Investigations|August 30, 2021
Letter from the Editor: 2021Adam J Adler
Immunological Investigations|December 22, 2022
Letter from the Editor: 2022Adam J Adler
Immunological Investigations|November 7, 2022
Cancer Immunology and Immunotherapy: From Defining Basic Immunology to Leading the Fight Against CancerAdam J Adler
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2006
Cutting edge: Paracrine, but not autocrine, IL-2 signaling is sustained during early antiviral CD4 T cell responseMeixiao Long, Adam J Adler
Immunotherapy|November 29, 2013
Striving for synergy: how to improve cancer immunotherapy through multiple agonist costimulationAdam J Adler, Anthony T Vella
Oncoimmunology|March 14, 2013
Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulationAdam J Adler, Anthony T Vella
Immunology Letters|February 7, 2009
In vitro and in vivo differentiated effector CD8 T cells display divergent histone acetylation patterns within the Ifng locusSuman Bandyopadhyay, Harry Z Qui, Adam J Adler
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Current Cancer Drug Targets|February 20, 2007
Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormonesAdam J Adler
Immunological Investigations|February 21, 2024
Letter from the Editor and Introduction to the 2023 Thematic IssueAdam J Adler
Current Immunology Reviews|April 23, 2010
Peripheral Tolerization of Effector and Memory T Cells: Implications for Autoimmunity and Tumor-ImmunityAdam J Adler
Immunological Investigations|August 30, 2021
Letter from the Editor: 2021Adam J Adler
Immunological Investigations|December 22, 2022
Letter from the Editor: 2022Adam J Adler
Immunological Investigations|November 7, 2022
Cancer Immunology and Immunotherapy: From Defining Basic Immunology to Leading the Fight Against CancerAdam J Adler
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2006
Cutting edge: Paracrine, but not autocrine, IL-2 signaling is sustained during early antiviral CD4 T cell responseMeixiao Long, Adam J Adler
Immunotherapy|November 29, 2013
Striving for synergy: how to improve cancer immunotherapy through multiple agonist costimulationAdam J Adler, Anthony T Vella
Oncoimmunology|March 14, 2013
Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulationAdam J Adler, Anthony T Vella
Immunology Letters|February 7, 2009
In vitro and in vivo differentiated effector CD8 T cells display divergent histone acetylation patterns within the Ifng locusSuman Bandyopadhyay, Harry Z Qui, Adam J Adler
Pageof 6